Silymarin in the treatment of chronic liver diseases: Past and future;Silymarin az idült májbetegségek kezelésében: Múlt és jövo

Orvosi Hetilap

Volumn 149, Issue 51, 2008, Pages 2413-2418

  Fehér, János ^a,b   Lengyel, Gabriella ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Semmelweis Egyetem   (Hungary)

Author keywords

Chronic liver disease; Hepatitis C virus; Silymarin; Steatohepatitis

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 2; GLYCYRRHIZIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITRIC OXIDE SYNTHASE; NUCLEOSIDE ANALOG; PEGINTERFERON; PICROSIDE I; RIBAVIRIN; SILIBININ; SILIDIANIN; SILYMARIN; VASCULOTROPIN;

ALCOHOLIC FATTY LIVER; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG MEGADOSE; DRUG STRUCTURE; HEPATITIS B; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER REGENERATION; LIVER TOXICITY; LONG TERM CARE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SURVIVAL TIME; TUMOR VASCULARIZATION;

EID: 58349110352     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28519     Document Type: Review

References (55)

1. Feher, J., Csomos, G., Vereckei, A.: Free radical reaction in biology and medicine. Springer Verlag, Berlin, Heidelberg, New York, 1987.
2. Fehér J., Lengyel G. (szerk.): Hepatológia. Medicina Könyvkiadó, Budapest, 2001.
3. Ferenci, P., Dragosics, B., Dittrich, H. és mtsai: Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol., 1989, 9, 105-113.
4. Manns, M. P., McHutchison, J. G., Gordon, S. C. és mtsai: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet, 2001, 358, 958-965.
5. Fried, M. W., Shiffman, M. L., Reddy, K. R. és mtsai: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N. Engl. J. Med., 2002, 347, 975-982.
6. Hadziyannis, S. J., Serte, H., Morgan, T. R. és mtsai: Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann. Intern. Med., 2004, 140, 346-355.
7. Fintelmann, V., Albert, A.: Nachweis der therapeutischen Wirksamkeit von Legalon bei toxischen Lebererkrankungen im. Doppelblindversuch. Therapiewoche, 1980, 30, 5589-5594.
8. Fehér J., Deák G., Muzes Gy. és mtsai: Sylimarin kezelés májvédo hatása idült alkoholos májbetegségben. Orv. Hetil., 1989, 130, 2723-2727.
9. Koch, H., Zinsberger, G.: Löslichkeitsparameter von Silybin, Silydianin und Silychristin. Arch. Pharm., 1980, 313, 526-533.
10. Hruby, K., Csomos, G., Fuhrmann, M. és mtsa: Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum. Toxicol., 1983, 2, 183-195.
11. Negi, A. S. Kumar, J. K., Luqman, S. és mtsai: Recent advances in plant hepatoprotectives: A chemical and biological profile of some important leads. Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/med.20115
12. Muzes Gy., Deék Gy., Láng I. és mtsai: Silymarin (Legalon®) kezelés hatása idült alkoholos májbetegek antioxidáns védorendszerére és a lipid peroxidáciora (kettos vak protokoll). Orv. Hetil., 1990, 131, 863-866.
13. Fehér, J., Láang, I., Nékám, K. és mtsai: Effect of free radical scavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis. Acta Med. Hung., 1988, 45, 265-276.
14. Lirussi, F, Okolicsanyi, L.: Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease. Acta Physiol. Hung., 1992, 80, 363-367.
15. Pares, A., Planas, R., Torres, M. és mtsai: Effects of silymarin on alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol., 1998, 28, 615-621.
16. Flora, K., Hahn, M., Rosen, H. és mtsa: AElk thistle ( Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol., 1998, 93, 139-143.
17. Lengyel G., Tulassay Zs.: Antioxidáns kezelés krónikus májbetegségekben. Orv. Hetil., 2006, 147, 1113-1118.
18. Lirussi, F., Beccarello, A., Zanette, G. és mtsai: Silybin-beta-cyclo-dextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an antioxidant agent. Diabet. Nutr. Metab., 2002, 15, 222-231.
19. Pár A., Roth E., Rumi G. Jr. és mtsai: Oxidatív stressz és antioxidáns védelem alkoholos májbetegségben és krónikus C hepatitisben. Orv. Hetil., 2000, 141, 1655-1659.
20. Levy, C., Seeff, L. D., Lindor, K. D.: Use of herbal supplements for chronic liver disease. Clin. Gastroenterol. Hepatol., 2004, 2, 947-956.
21. Salomon, J. A., Weinstein, M. C., Hammitt, J. K. és mtsa: Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA, 2003, 290, 228-237.
22. Saller R.., Melzer, J., Reichling, J. és mtsai: An updated systematic review of the pharmacology of silymarin. Forsch. Komplementärmed., 2007, 14, 70-80.
23. Kim, Y. C., Kim, E. J., Lee, E. D. és mtsai: Comparative bioavailability of silibinin in healthy male volunteers. Int. J. Clin. Pharmacol. Ther., 2003, 41, 593-596.
24. Mayer, K. E., Myers, R. P., Lee, S. S.: Silymarin treatment of viral hepatitis: a systematic review. J. Viral. Hepat., 2005, 12, 559-567.
25. Huber, R., Futter, I., Ludtke, R.: Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens. Eur. J. Med. Res., 2005, 10, 68-70.
26. Polyak, S. J., Morishima, C., Shuhart, M. C. és mtsai: Inhibition of T-inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized silymarin. Gastroenterology, 2007, 132, 1925-1936.
27. Mayer, K. E., Myers, R. P., Lee, S. S.: Silymarin treatment of viral hepatitis: a systematic review. J. Viral. Hepatol., 2005, 12, 559-567.
28. Rambaldi, A., Jacobs, B. R, Iaquinto, G. és mtsa: Milk thistle for alcoholic and/or hepatitis B or C liver diseases: a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am. J. Gastroenterol., 2005, 100, 2583-2591.
29. Gordon, A., Hobbs, D. A, Bowden, D. S. és mtsai: Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J. Gastroenterol. Hepatol., 2006, 21, 275-280.
30. Seeff, L. B., Curto, T. M., Szabo, Gy. és a HALT-C Trial Group: Herbal Product Use by Persons Enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology, 2008, 47, 605-612.
31. Romero-Gómez, M.: Insulin resistance and hepatitis C. World J. Gastroenterol., 2006, 12, 7075-7080
32. Ferenci, P., Scherzer, T. M., Hofer, A. és mtsai: Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to antiviral combination therapy. J. Hepatology, 2008, 48 (Suppl. 2), S28.
33. Ferenci, P., Scherzer, T. M., Kerschner, H. és mtsai: Silibinin is a potent antiviral agent in patients with chronic HCV not responding to pegylated interferon/ribavirin therapy. Gastroenterology, 2008 (open access, in press).
34. Beckmann-Knopp, S., Rietbrock, S. és mtsai: Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol. Toxicol., 2000, 86, 250-256.
35. Saller R., Brignoli, R., Melzer, J. és mtsa: An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch. Komplementärmed., 2008, 15, 9-20.
36. Gupta, O. P., Sing, S., Bani, S. és mtsai: Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine, 2000, 7, 21-24.
37. Ramakrishnan, G., Jagan, S., Augustine, T. A. és mtsai: Silymarin downregulates COX-2 expression and attenuates hyperlipidemia during NDEA-induced rat hepatocellular carcinoma. Mol. Cell. Biochem., 2008, 313, 53-61.
38. Kosina, P., Maurel, P., Ulrichova, J. és mtsa: Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol., 2005, 19, 149-153.
39. Volate, S. R., Davenport, D. M., Muga, S. J. és mtsai: Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng, and rutin). Carcinogenesis, 2005, 26, 1450-1456.
40. Agarwal, C., Sing, R., Dhanalakshmi, S. és mtsai: Silibinin up-regulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene, 2003, 22, 8271-8282.
41. Singh, R. P., Gu, M., Agarwal, R.: Silibinin inhibits colorectal cancer growth by inhibiting tumor cell. Prolifer. Angiogen. Cancer Res., 2008, 68, 2043-2050.
42. Chu, S. C., Chiou, H. L., Chen, P. N. és mtsai: Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol. Carcinogen., 2004, 40, 143-149.
43. El-Shitany, N. A., El-Haggar, S., El-desoky, K.: Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem. Toxicol., 2008, 46, 2422-2428.
44. Ramasamy, K., Agarwal, R.: Multitargeted therapy of cancer by silymarin. Cancer Lett., 2008. Doi: 10.1016/j.canlet.2008.03.053 ( Open access, in press).
45. Singh, R. P., Mallikarjuna, G. U., Sharma, G. és mtsai: Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor κB-mediated inducible chemoresistance. Clin. Cancer Res., 2004, 10, 8641-8647.
46. Yang, S. H., Lin, J. K., Chen, W. S. és mtsai: Anti-angiogenic effect of silymarin on colon cancer LoVo cell fine. J. Surg. Res., 2003, 113, 133-138.
47. Singh, R. P., Gu, M., Agarwal, R.: Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res., 2008, 68, 2043-2050.
48. Hogan, F. S., Krishnegowda, N. K., Mikhailova, M. és mtsai: Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J. Surg. Res., 2007, 143, 58-65.
49. Soria, E. A., Eynard, A. E., Quiroga, P. E. és mtsai: Differential effects of quercetin and silymarin on arsenite-induced cytotoxicity in two human breast adenocarcinoma cell lines. Life Sci., 2007, 81, 1397-1402.
50. Deep, G., Oberlies, N. H., Kroll, D. J. és mtsai: Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int. J. Cancer, 2008, 123, 41-50.
51. Davis-Searles, P. R., Nakanishi, Y., Kim, N. C. és mtsai: Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res., 2005, 65, 4448-4457.
52. Singh, R. P., Tyagi, A., Sharma, G. és mtsai: Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin. Cancer Res., 2008, 14, 300-308.
53. Katiyar, S. K.: Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effect (review). Int. J. Oncol., 2005, 26, 169-176.
54. Ligeret, H., Brault, A., Vallerand, D. és mtsai: Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. J. Ethnopharmacol., 2008, 115, 507-514.
55. Senturk, H., Kabay, S., Bayramoglu, G. és mtsai: Silymarin attenuates the renal ischemia/reperfusion injury-induced morphological changes in the rat kidney. World J. Urol., DOI 10.1007/s00345-008-0256-1 (Open access, in press).